The Uniformed Services University (USU) recently issued a Cooperative Agreement to The Geneva Foundation (Geneva) for $2.2M to investigate the efficacy of antimicrobial Blue light therapies (aBL) at combating infections at the implant site for osseointegrated (OI) implant technology. This program was funded by Defense Health Agency (DHA) with partnerships from USU, Geneva, The Wellman Center, the University of Utah, and Utah State University.
Led by USU PI Dr. Paul Pasquina and Geneva PI Dr. Brad Isaacson, the research teams will investigate the efficacy of aBL therapies. Complications from infection remain a major concern for OI implant systems, with published literature indicating that infection rates range from 5-34%. aBL has shown promise as a non-drug approach to combat microbial infections, and is effective against negative bacteria, molds, yeasts, dermatophytes, and biofilms.
This exciting technology may improve the quality of life for individuals who use OI implants by providing a safe, drug-free alternative to combating microbial infections. This research will be tested via a novel translational model, which has previously led to successful OI development and clinical trials.
About the Uniformed Services University: USU trains, educates and prepares uniformed services health professionals, officers and leaders to directly support the Military Health System, the National Security and National Defense Strategies of the United States and the readiness of our Armed Forces. www.usuhs.edu
About The Geneva Foundation: The Geneva Foundation (Geneva) is a non-profit organization headquartered in Tacoma, WA. Established in 1993, Geneva advances military medicine by delivering full spectrum scientific, technical, and program management expertise in the areas of federal grants, industry-sponsored clinical trials, federal contracts, and event management. www.genevaUSA.org